Mechanism
Recombinant fusion protein consisting of two disulfide-linked GLP-1(7–37) analogs each covalently fused via a linker to an IgG4 Fc fragment, yielding a large, long-acting GLP-1 receptor agonist protected from DPP-4 degradation.66
Peptide record
Recombinant fusion protein consisting of two disulfide-linked GLP-1(7–37) analogs each covalently fused via a linker to an IgG4 Fc fragment, yielding a large, long-acting GLP-1 receptor agonist protected from DPP-4 degradation.66
Once-weekly GLP-1RA for type 2 diabetes that lowers HbA1c and body weight by enhancing glucose-dependent insulin secretion and reducing appetite.6668
Each chain contains an N-terminal GLP-1 analog sequence (based on GLP-1(7–37)) linked to a modified human IgG4 Fc; full sequence is large and typically described structurally rather than residue-by-residue.66
null amino acids
Engineered human GLP-1 analog–IgG4 Fc fusion protein produced in mammalian cell culture.66
GCG